BioHarvest Sciences Inc. (NASDAQ:BHST) introduced VINIA Blood Flow Hydration, a new electrolyte drink that leverages the company’s patented Piceid resveratrol technology to promote arterial dilation and efficient fluid delivery. The product is available in six flavors—Mixed Berry, Fruit Punch, Watermelon, Summer Orange, Lemonade, and Lemon Lime—and ships nationwide through Vinia.com with free North American delivery.
Each 12‑fluid‑ounce serving delivers 470 mg of sodium, 190 mg of potassium, 80 mg of magnesium, 23 mg of VINIA polyphenols, and 6 mg of rapid‑absorption Piceid resveratrol. The drink is Informed Sport‑certified, ensuring it meets rigorous standards for banned substances, and comes with a 90‑day money‑back guarantee.
The launch positions BioHarvest in the $13 billion U.S. electrolyte market, a segment projected to grow at a CAGR of 8.8% through 2030. By combining electrolytes with a science‑backed resveratrol platform, BioHarvest seeks to differentiate its hydration offering from established sports‑drink brands and tap into the growing consumer demand for functional beverages that support blood flow and recovery.
Financially, BioHarvest reported Q3 2025 revenue of $9.07 million, up 39% year‑over‑year, driven by a 30% increase in product revenue to $8.4 million and a 722% surge in CDMO revenue to $0.7 million. Gross margins expanded to 61% as manufacturing scale and improved yields offset higher raw‑material costs. The company’s DTC channel, anchored by VINIA capsules, continues to grow, with over 75,000 active U.S. users and cumulative sales exceeding $50 million as of February 2025.
CEO Ilan Sobel emphasized that the new hydration line reflects BioHarvest’s “Superior Science, Superior Efficacy and Superior Taste” philosophy. He noted that the company’s botanical synthesis platform enables rapid development of plant‑based molecules, allowing BioHarvest to bring innovative products to market faster than competitors.
Strategically, the VINIA Blood Flow Hydration launch expands BioHarvest’s direct‑to‑consumer footprint, diversifies revenue streams beyond its flagship capsules, and strengthens the company’s position in a high‑growth market. Coupled with the rapid expansion of its CDMO business, the company is moving closer to adjusted EBITDA breakeven while maintaining a clear focus on scalable, science‑driven product innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.